Novo Nordisk Shares Sink After $23 Billion Obesity Sales Target for 2030

Novo Nordisk shares fell 7.0% to $40.20 after its Capital Markets Day failed to provide near-term strategic clarity. CEO Mike Doustdar acknowledged patent expirations for semaglutide, a key revenue driver, starting in 2030. Analysts maintained Hold ratings. The company aims to launch five blockbusters and achieve $23B in new sales. The stock is down 19% year-to-date, trading well below its 52-week high.

Novo Nordisk reported that its experimental drug CagriSema achieved 12.4% average weight loss in a late-stage diabetes trial, outperforming Eli Lilly's rival drug. The company plans to launch CagriSema early next year. Novo's U.S.-listed shares fell over 4% premarket as analysts questioned its pricing power and strategy ahead of patent expiries. The drug showed superior weight loss to Lilly's tirzepatide in diabetes patients but less impactful data in obesity trials.

Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.

Novo Nordisk (NVO) shares fell 9% after presenting its 2030 strategic outlook, projecting revenue growth in line with peers and over five multi-blockbuster drugs by 2030. CEO Mike Doustdar highlighted diversification plans ahead of semaglutide patent expirations. The company aims for DKK 150 billion ($23B) in pipeline sales by 2035, but investors reacted negatively, expecting more aggressive targets.

Novo Nordisk reported that its experimental drug CagriSema achieved 12.4% average weight loss in a late-stage trial for diabetes patients, outperforming Eli Lilly's rival drug. The drug, a weekly injection combining cagrilintide and semaglutide, also showed non-inferior blood sugar reduction. Earlier, CagriSema had underperformed Lilly's Zepbound in a head-to-head trial. Novo Nordisk and Eli Lilly are involved, with implications for their obesity and diabetes drug markets.

Novo Nordisk A/S Class B (NOVO_B) unveiled a strategy targeting five multi-blockbuster drug launches by 2030 and over 150 billion DKK in pipeline sales by 2035. The plan focuses on sustainable growth, pipeline diversification, and major R&D and commercial transformations, spanning obesity, diabetes, and other disease areas.